Company: LGN
Filing Date: 2025-04-30
Form Type: DRS/A
Source: 0000950123-25-003868
Chunk: 94

Company: Legence Corp.
Filing Date: 2025-04-30
Form: DRS/A
Chunk 94
---
 of the voting power is held by an
individual, group or another company is a “controlled company” and need not comply with certain requirements, including the requirement that a majority of the board of directors consist of independent directors and the requirements that
our compensation and nominating and governance committees be composed entirely of independent directors. Following this offering, we do not intend to utilize these exemptions, However, for so long as we qualify as a “controlled company,”
we will maintain the option to utilize some or all of these exemptions. If we utilize these exemptions, we may not have a majority of independent directors and our compensation and nominating and governance committees may not consist entirely of
independent directors, and such committees will not be subject to annual performance evaluations. Accordingly, in the event we elect to rely on these exemptions in the future, you may not have the same protections afforded to stockholders of
companies that are subject to all of the corporate governance requirements of the Nasdaq. See “Management—Status as a Controlled Company.”

Future sales of our Class A Common Stock or LGN Units in the public market could reduce the market price of our Class A Common Stock, and any additional capital raised by us through the sale of equity or convertible or exchangeable securities may dilute your ownership in us.

We may sell additional shares of Class A Common Stock in subsequent public offerings. We may also issue additional shares of Class A
Common Stock or convertible or exchangeable securities (including LGN Units). After the completion of this offering, we will have outstanding shares of our Class A Common Stock of which our Sponsor will own
shares of our Class A Common Stock (or shares of Class A

56

Confidential Treatment Requested by Legence Corp.

Pursuant to 17 C.F.R. Section 200.83

Common Stock if the underwriters exercise in full their option to purchase additional shares of Class A Common Stock and after giving effect to the application of the net proceeds therefrom)
or approximately % of our total outstanding shares of Common Stock (or % of outstanding shares of our Class A Common Stock if the underwriters exercise in full their option to purchase additional shares of Class A Common
Stock and after giving effect to the application of the net proceeds therefrom), all of which are restricted from immediate resale under the federal securities laws and are subject to the lock-up agreements
with the underwriters described in “Underwriting” but may be sold into the market in the future. See “Shares Eligible for Future Sale.” After the completion